Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FDA 018 ADC

Next Previous
Drug Profile

FDA 018 ADC

Alternative Names: FDA 018 - Antibody-drug conjugate; FDA 018-ADC; FDA018-Antibody-drug Conjugate

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Pyrans; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 09 Aug 2024 Phase-III clinical trials in Triple-negative-breast-cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT06519370)
  • 25 Jul 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans phase-III trial for Triple negative breast cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, In adults, In the elderly) in August 2024 (IV, infusion) (NCT06519370)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top